ntiated clinical profile.

In light of its greater expectation for Nemluvio and confidence in its broad-based growth trajectory, Galderma is specifying its 2023-2027 mid-term guidance to be within or above the previously stated ranges as per the table available in the Appendix, along with additional modelling metrics for 2026. Guidance for the mid-term is based on the same tariff assumption as for 20267, and subject to the same expected impact from foreign exchange.

Webcast details

Galderma will host its financial results call today at 14:00 CET to discuss the full year 2025 results and respond to questions from financial analysts. Investors and the public may access the webcast by registering on the Galderma Investor Relations website at&nbsphttps://investors.galderma.com/events-presentations.

2025 Annual Report

Galderma issued its 2025 Annual Report today, and it is available athttps://investors.galderma.com/financial-reports.


=*=*=*=*=*=
当前为第24/55页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页